Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Liberti L, Breckenridge A, Eichler HG, Peterson R, McAuslane N, Walker S. Expediting patients’ access to medicines by improving the predictability of drug development and the regulatory approval process. Clin Pharmacol Ther. 2010;87:27–31. doi: 10.1038/clpt.2009.179 .
2. Handoo S, Arora V, Khera D, Nandi PK, Sahu SK. A comprehensive study on regulatory requirements for development and filing of generic drugs globally. Int J Pharm Investig. 2012;2:99–105. doi: 10.4103/2230-973X.104392 .
3. US Food and Drug Administration. Title 21 code of federal regulations part 320 bioavailability and bioequivalence requirements. 2015. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=320 . Accessed 3 Dec 2015
4. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–20.
5. Chen ML, Amidon GL, Benet LZ, Lennernäs H, The YLX, BCS. BDDCS, and regulatory guidances. Pharm Res. 2011;28:1774–8. doi: 10.1007/s11095-011-0438-1 .
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献